Pharma Focus Asia

Lupin gets USFDA nod for hypertension treatment drug in US

Tuesday, December 27, 2016

Drug major Lupin has received tentative approval from the US health regulator to sell Olmesartan medoximil tablets, used for treating high blood pressure, in the American market.

"It has received tentative (rpt) tentative approval for Olmesartan medoximil tablets, 5 mg, 20 mg and 40 mg from the US Food and Drug Administration (USFDA)," Lupin Ltd said in a BSE filing today.

Olmesartan medoximil tablets, generic version of Daiichi Sankyo's Benicar, are indicated for the treatment of hypertension, along with other anti-hypertensive agents to lower blood pressure, it added.

Quoting IMS MAT September 2016 sales data, Lupin further said that Benicar tablets had annual US sales of USD 1.06 billion.

Shares of the company were trading 0.71 per cent up at Rs 1,457 apiece on BSE.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Asia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024
Charles river - Endosafe Trillium